Skip to main content
| News

VectivBio raises 125 million US dollars in stock sale

21.10.2022

VectivBio has announced the closing of the subscription offer for 16,700,000 ordinary shares. The Basel-based biotechnology firm has generated gross proceeds of around 125 million US dollars from this. The fresh capital is intended to help further develop the company’s product candidate for severe rare gastrointestinal diseases.

lab

The Basel-based biotechnology firm VectivBio Holding AG has raised around 125 million US dollars after selling off 16,700,000 ordinary shares. These were offered for purchase at a price of 7.50 US dollars per share. Details of this were recently announced by the company as part of a press release.

Advancing clinical development

According to the information provided, VectivBio intends to put the net proceeds from the stock sale and available cash funds towards the clinical development and pre-commercial activities in connection with the lead product candidate as well as for general corporate purposes.

The lead product candidate, apraglutide, is a next-generation, long-acting, glucagon-like peptide (GLP)-2 analog. It is being developed for a number of rare gastrointestinal diseases, such as short bowel syndrome with intestinal failure (SBS-IF) and Acute Graft-Versus-Host Disease (aGVHD), where GLP-2 can play a central role in addressing the pathophysiology of the disease.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Sustainability

Evolva launches new line for manufacturers of personal care products

Evolva, a manufacturer of active ingredients based in Reinach in the canton of Basel-Landschaft, will be presenting its new product...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Record figure for startups in the Basel Area

Basel Area Business & Innovation has supported a record number of 96 company startups in 2022. The number of settlements...

Read More
Noema Pharma raises 103 million Swiss francs from investors
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Noema Pharma raises 103 million Swiss francs from investors

Noema Pharma has raised a total of 103 million Swiss francs as part of an oversubscribed Series B financing round....

Read More
Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Why CDMO companies choose the Basel Area as their location

Originally, this article was published by the US magazine Outsourced Pharma under the title "Why Location Matters". The article highlights...

Read More
Basel Area Business & Innovation, Innovation, Invest

Basel still the most attractive small city for business in Europe

As with last year, Basel once again features among the most attractive locations in Europe for investments. It was ranked...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Ariceum Therapeutics establishes subsidiary in Basel

The German life sciences firm Ariceum Therapeutics has established a subsidiary in Basel. This company has received support from Basel...

Read More
1 2 3 61

Do you have a question? We'd like to hear from you.